Vertex at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

Vertex Oral Presentations

November 1, 2010 @ 5:00 p.m. ET

#LB-2 “Telaprevir in Combination with Peginterferon Alfa2a and Ribavirin for 24 or 48 weeks in Treatment-Naïve Genotype 1 HCV Patients who Achieved an Extended Rapid Viral Response: Final Results of Phase 3 ILLUMINATE Study”
Hynes Auditorium

November 2, 2010 @ 8:00 a.m. ET

#211 “Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naïve Patients: Final Results of Phase 3 ADVANCE Study”
Hynes Auditorium

November 2, 2010 @ 11:45 a.m. ET

#227 “Long-term Follow-up of Patients with Chronic Hepatitis C Treated with Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin: Interim Analysis of the EXTEND Study”
Hynes Room 304/306

Vertex Poster Presentations

October 31, 2010 @ 8:00 a.m. ET

#805 “No Impact of Insulin Resistance on Antiviral Efficacy of Telaprevir-based Regimen in HCV Genotype 1 Treatment-Naïve Patients: Subanalysis of C208 Study”
Hynes Exhibit Hall C

#828 “Activity of Telaprevir Monotherapy or in Combination with Peginterferon-alfa-2a and Ribavirin in Treatment-naïve Genotype 4 Hepatitis-C Patients: Final Results of Study C210”
Hynes Exhibit Hall C

#1051 “Spontaneous Viral Clearance in a Patient With Chronic Hepatitis C who Relapsed After Telaprevir-based Treatment”
Hynes Exhibit Hall C

#899 “The Effect of Hepatitis C Treatment Response on Medical Costs: a 5-Year Longitudinal Analysis in a Managed Care Setting”
Hynes Exhibit Hall C

November 1, 2010 @ 8:00 a.m. ET

#LB-11 “Clinical Virology Results from Telaprevir Phase 3 Study ADVANCE”
Hynes Exhibit Hall C

Last Revised 10/05/10

Source